651 related articles for article (PubMed ID: 16986349)
1. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
Van Poznak C; Estilo C
Oncology (Williston Park); 2006 Aug; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349
[TBL] [Abstract][Full Text] [Related]
2. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
3. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
4. The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer.
Van Poznak C
Cancer Invest; 2006 Feb; 24(1):110-2. PubMed ID: 16467002
[TBL] [Abstract][Full Text] [Related]
5. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA
Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
King AE; Umland EM
Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF
Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate-associated osteonecrosis of the jaw: conclusions based on an analysis of case series.
Landesberg R; Wilson T; Grbic JT
Dent Today; 2006 Aug; 25(8):52, 54-7. PubMed ID: 16925161
[TBL] [Abstract][Full Text] [Related]
9. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ
J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
[TBL] [Abstract][Full Text] [Related]
11. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
Estilo CL; Van Poznak CH; Wiliams T; Bohle GC; Lwin PT; Zhou Q; Riedel ER; Carlson DL; Schoder H; Farooki A; Fornier M; Halpern JL; Tunick SJ; Huryn JM
Oncologist; 2008 Aug; 13(8):911-20. PubMed ID: 18695259
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Vahtsevanos K; Kyrgidis A; Verrou E; Katodritou E; Triaridis S; Andreadis CG; Boukovinas I; Koloutsos GE; Teleioudis Z; Kitikidou K; Paraskevopoulos P; Zervas K; Antoniades K
J Clin Oncol; 2009 Nov; 27(32):5356-62. PubMed ID: 19805682
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Marx RE; Sawatari Y; Fortin M; Broumand V
J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate-related osteonecrosis of the jaw in cancer patients: Implications for nurses.
Morris M; Cruickshank S
Eur J Oncol Nurs; 2010 Jul; 14(3):205-10. PubMed ID: 20129822
[TBL] [Abstract][Full Text] [Related]
16. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
[TBL] [Abstract][Full Text] [Related]
17. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
Mavrokokki T; Cheng A; Stein B; Goss A
J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment.
Fehm T; Felsenberg D; Krimmel M; Solomayer E; Wallwiener D; Hadjii P
Breast; 2009 Aug; 18(4):213-7. PubMed ID: 19651512
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw.
Haidar A; Jønler M; Folkmar TB; Lund L
Scand J Urol Nephrol; 2009; 43(6):442-4. PubMed ID: 19903091
[TBL] [Abstract][Full Text] [Related]
20. Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors.
Delibasi T; Altundag K; Kanlioglu Y
J Oral Maxillofac Surg; 2006 Jun; 64(6):995-6. PubMed ID: 16713825
[No Abstract] [Full Text] [Related]
[Next] [New Search]